Maraviroc (MVC) is the first licensed antiretroviral drug from the class of coreceptor antagonists. It binds to the host coreceptor CCR5, which is used by the majority of HIV strains in order to infect the human immune cells (Fig. 1 ). Other HIV isolates use a different coreceptor, the CXCR4. Which receptor is used, is determined in the virus by the Env protein (Fig. 2) . Depending on the coreceptor used, the viruses are classified as R5 or X4, respectively. MVC binds to the CCR5 receptor inhibiting the entry of R5 viruses into the target cell. During the course of disease, X4 viruses may emerge and outgrow the R5 viruses. Determination of coreceptor usage (also called tropism) is therefore mandatory prior to administration of MVC, as demanded by EMA and FDA.
.
For several years now, we have performed tropism determinations based on sequence analysis from the HIV env-V3 gene region (V3) 2 . This region carries enough information to perform a reliable prediction. The genotypic determination of coreceptor usage presents advantages such as: shorter turnover time (equivalent to resistance testing), lower costs, possibility to adapt the results to the patients' needs and possibility of analysing clinical samples with very low or even undetectable viral load (VL), particularly since the number of samples analysed with VL<1000 copies/μl roughly increased in the last years (Fig. 3) .
The main steps for tropism testing (Fig. 4 ) demonstrated in this video: 1. Collection of a blood sample 2. Isolation of the HIV RNA from the plasma and/or HIV proviral DNA from blood mononuclear cells 3. Amplification of the env region 4. Amplification of the V3 region 5. Sequence reaction of the V3 amplicon 6. Purification of the sequencing samples 7. Sequencing the purified samples 8. Sequence editing 9. Sequencing data interpretation and tropism prediction
Video Link
The video component of this article can be found at https://www.jove.com/video/3264/
Protocol
The protocol is summarized in Fig. 4. 
Collection of blood samples
1. Collect at least 3 ml blood in EDTA tubes at the clinical site. 2. The samples can be stored up to a week at 4°C. 3. Send the EDTA-blood samples as soon as possible to the laboratory by ordinary mail.
Isolation of HIV RNA and/or DNA
1. Obtain viral RNA and/or DNA from 1000 μl whole blood, serum or plasma, using the MagNA Pure Compact Nucleic Acid Isolation I kit I and the MagNA Pure Compact System. 2. Elute the gained RNA or DNA in 50 μl TE buffer. Alternatively, other nucleic acids purification procedures may be used.
Amplification of the env region
Amplify the env region (Figs. 2 and 4 ) from either plasma RNA or proviral DNA. A 1245 bp-long product, comprising the majority of the Env protein (nt 6556-7811 according to HXB2) is generated.
1. RNA samples: RT-PCR reaction 1. Viral RNA presents a very complex secondary structure (Fig. 4) that may hinder the RT reaction. To avoid this problem, incubate 10 μl RNA at 65°C for 10 minutes (already in the PCR tube and in the PCR machine) and then reduce the temperature to 50°C. Analyze the PCR product on a 1% agarose gel (Fig. 4) . The expected product is 902 bp-long. 4. Purification of the sequencing samples. 1. Purify the PCR product with the Qiagen PCR-Purification kit, using the protocol, solutions and micro-columns provided by the supplier. Elute in 30-100 μl PE buffer, depending on band intensity. 2. Alternatively, the samples can be purified using Exonuclease I and Fast AP (Thermo alkaline phosphatase). For this purpose, add 6 μl Exo-AP Mix to 15 μl PCR product and incubate 15 minutes at 37°C. 
Purification of the sequencing samples
Purify sequences using Sephadex G-50 superfine.
1. Fill the appropriate number of wells in the "column loader" with Sephadex G-50 superfine. Transfer the Sephadex to the filter plate MAHVN4510 by turning over. 2. Add 300 μl Milli-Q H 2 O to each well in the filter plate, and incubate it for at least 3h at 2-8°C. 
Sequence editing
1. Use the program Lasergene (DNA-Star) to align and edit the sequences (Fig. 5) . Other sequence editing programs may be used. Use a "V3-Consensus B" and the env consensus sequence as references. 2. Lasergene creates a consensus sequence of the analysed sample using all the raw data available and store it as FASTA file. The FASTA file is a text file that includes a header with the name of the sample and the nucleotide sequence.
Sequencing data interpretation and tropism prediction
1. Sequencing data interpretation is performed by the web-based interpretation system geno2pheno [coreceptor] (http://coreceptor.bioinf.mpiinf.mpg.de/index.php). For the tropism prediction, different FPR settings can be selected. The default setting is according to the GermanAustrian therapy guidelines. For FPR ≥ 20%, the virus is classified as R5 when FPR ≥ 20% and X4 for FPR < 12.5%. 2. Upload the FASTA file into the server. This server translates the nucleotide sequence into amino acids, aligns it with the V3-Consensus B sequence and produces a subtype classification. In addition, it generates a prediction of the coreceptor usage (Fig. 4) expressed as false positive rate (FPR).
Representative Results
The geno2pheno [coreceptor] output shows a graded interpretation of the tropism. Depending on the likelihood of the coreceptor usage, the interpretation text and background color varies from green (<20% FPR), suggesting a safe administration for MVC, to yellow, suggesting a possible, low risk and finally to red. Red is the color suggesting not to prescribe MVC. In addition, the server generates a pdf report that can be printed, filled in with patient's and sample data, and sent to the physician. Examples of geno2pheno [coreceptor] output are depicted in Fig. 6 . Figure 6 . Tropism prediction reports generated by the geno2pheno [coreceptor] tool.The reports are generated as pdf files that can be saved and completed in the computer. Additional data such us patient's name, date of blood extraction, etc., can be manually included using a pdf writer program. Specific comments can be also added. These data are exclusively on the user's computer and not on the geno2pheno [coreceptor] server. Please click here to see a larger version of this figure.
Discussion
The V3 sequence permits a reliable viral tropism prediction, as shown in clinical studies [3] [4] [5] [6] [7] [8] [9] . In fact, genotypic determination is contemplated in the current European and German-Austrian guidelines 10 .
Compared to phenotypic testing, not only is the turnover time shorter (equivalent to resistance testing), but also are the costs. In addition, a major advantage of genotypic testing is that the results are graded as FPR and therefore can be adapted to the patients' needs. Trofile results, on the other hand, are simply R5 or X4 reports, and access to the raw data is not given.
Currently, The European guidelines suggest a FPR cut-off of 20% 10 , while the Austrian-German guidelines allow adapting the FPR cut-off specifically to each patient's needs 11 . In this line, for patients with a broad range of antiretroviral drugs options, higher FPR cut-offs (> 20%) are recommended. Conversely, for heavily pre-treated patients with limited therapeutic options, lower FPR cut-offs (> 5%) may be used. This kind of therapy guidance is currently ongoing by the resistance testing to NRTIs, NNRTIs, PIs, and INIs, where partially-active drugs may be included in the treatment for patients with reduced therapeutic options. In addition, with growing numbers of genotypically-guided therapy changes, the clinically-relevant FPR cut-offs are constantly being adjusted by a panel of bioinformaticians, virologists and clinicians.
Another important advantage of the genotypic tropism testing is the possibility of analyzing clinical samples with very low or even undetectable viral load (VL). In this cases, when plasma RNA is not amplifiable, the proviral DNA can be sequenced and used for reliable predictions 9, 12 . Of note, the number of patients with low or undetectable viral load has sharply increased in the latest years. To date, the Trofile assay only allows the analysis of samples from patients with VL<1000 copies/ml. However, preliminary studies have shown that proviral DNA may be also adecuate to be tested by Trofile 13 .
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